

DR. ECKHARDT FERDINANDI

MANUSCRIPTS

E.S. Ferdinandi, W.P. Garby and D.G.L. James: The Reactivity of the Cyclic Polyenes Towards Free Radicals. I. Copolymerization with Acrylonitrile, *Can. J. Chem.* 1964; **42**: 2568-2576.

A. Hassner, E.S. Ferdinandi and R.J. Isbister: The Hydrolysis of Vinyl Azides. A Comparison with the Schmidt Reaction. *J. Am. Chem. Soc.* 1970; **92**: 1672-1675.

E.S. Ferdinandi and G. Just: A Synthesis of d,1-Prostaglandin E₂ Methyl Ester and Related Compounds. *Can. J. Chem.* 1971; **49**: 1070-1084.

J.F. Bagli and E.S. Ferdinandi: Thiophene Isosters of Phenylethanolamines. *Can. J. Chem.* 1975; **53**: 2598-2607.

E.S. Ferdinandi: Preparation of [2-¹⁴C]-2-(p-Chlorophenoxy-O-2-methylpropionic Acid and its Ethyl Ester, [¹⁴C]Clofibrate. *J. Label. Compounds Radiopharm.* 1975; **11**: 287-289.

J.F. Bagli, W.D. Mackay, E.S. Ferdinandi, M.N. Cayen, I. Vavra, T. Pugsley and W. Lippmann: Synthesis and Antihypertensive Activity of Some Thienylethanolamines. *J. Med. Chem.* 1976; **19**: 876-882.

E.S. Ferdinandi: Synthesis of [γ -¹⁴C]- γ -Oxo-2-dibenzofuranbutanoic Acid (Furobufen) and 2-Dibenzofuran Acetic [Carboxyl-¹⁴C] Acid. *J. Label. Compounds Radiopharm.* 1976; **12**: 357-364.

M.N. Cayen, E.S. Ferdinandi, E. Greselin, W.T. Robinson and D. Dvornik: Clofibrate and Clofibric Acid: Comparison of the Metabolic Disposition in Rats and Dogs. *J. Pharmacol. Exp. Therap.* 1977; **200**: 33-43.

W.T. Robinson, R.R. Martel, E.S. Ferdinandi, and M. Kraml: Effect of Ring Substitution of the Metabolic Fate and Anti-Inflammatory Activity of Some Prodic Acid Analogs. *J. Pharmacol. Exp. Therap.* 1977; **203**: 729-735.

E.S. Ferdinandi, D.R. Hicks, W. Verbestel and P. Raman: Synthesis of [¹⁴C]Labelled Pyrano[3,4-b]- and Thiopyrano[3,4-b]indoles, and Indeno[2,1-c]pyran Derivatives. *J. Label. Compounds Radiopharm.* 1978; **14**: 411-425.

E.S. Ferdinandi: Synthesis of Potassium [¹⁴C]Dicloxacillin. *J. Label. Compounds Radiopharm.* 1978; **14**: 751-755.

E.S. Ferdinandi, P. Raman and V. Ross: Synthesis of [14-¹⁴C]Dexclamol Hydrochloride and [14-¹⁴C]Butaclamol Hydrochloride. *J. Label. Compounds Radiopharm.* 1978; **14**: 757-765.

E.S. Ferdinandi: Synthesis of [4-¹⁴C]Diosgenin, *J. Label. Compounds Radiopharm.* 1979; **16**: 345-350.

M.N. Cayen, E.S. Ferdinandi, E. Greselin and D. Dvornik: Studies on the Disposition of Diosgenin in Rats, Dogs, Monkeys and Man. *Atherosclerosis* 1979; **33**: 71-87.

M.N. Cayen, E.S. Ferdinandi, E. Greselin and D. Dvornik: Distribution and Excretion of Furobufen in Rats and Dogs. *Drug Metab. Disp.* 1981; **9**: 125-128.

N.M. Cayen, M. Kraml, E.S. Ferdinandi, E. Greselin and D. Dvornik: The Metabolic Disposition of Etodolac in Rats, Dogs and Man. *Drug Metab. Rev.* 1981; **12**: 339-362.

E.S. Ferdinandi, M.N. Cayen and C. Pace-Asciak: Disposition of Etodolac, Other Anti-Inflammatory Pyranoindole-1-Acetic Acids and Furobufen in Normal and Adjuvant Arthritic Rats. *J. Pharmacol. Exp. Therap.* 1982; **220**: 417-426.

M.N. Cayen, D.R. Hicks, E.S. Ferdinandi, M. Kraml, E. Greselin and D. Dvornik: Metabolic Disposition and Pharmacokinetics of the Aldose Reductase Inhibitor Tolrestat in Rats, Dogs and Monkeys. *Drug Metab. Disp.* 1985; **13**: 412-419.

E.S. Ferdinandi, S.N. Sehgal, C.A. Demerson, J. Dubuc, J. Zilber, D. Dvornik and M.N. Cayen: Disposition and Biotransformation of ¹⁴C-Etodolac in Man. *Xenobiotica* 1986; **16**: 153-166.

M.N. Cayen, R. Gonzalez, E.S. Ferdinandi, E. Greselin, D.R. Hicks, M. Kraml and D. Dvornik: The Metabolic Disposition of Acifran, a New Antihyperlipidemic Agent, in Rats and Dogs. *Xenobiotica* 1986; **16**: 251-263.

E.S. Ferdinandi, D. Cochran and R. Gedamke: Identification of the Etodolac Metabolite, 4-Ureidoetodolac, in Mouse, Rat, Dog and Man. *Drug. Metab. Disp.* 1987; **15**: 921-923.

L.G. Humber, E. Ferdinandi, C.A. Demerson, S. Ahmed, U. Shah, D. Mobilio, J. Sabatucci, B. De Lange, F. Labbadia, P. Hughes, J. DeVirgilio, G. Neuman, T.T. Chau and B.M. Weichman: Etodolac, a Novel Anti-inflammatory Agent. The Synthesis and Biological Evaluation of its Metabolites. *J. Med. Chem.* 1988; **31**: 1712-1719.

M.N. Cayen, E.S. Ferdinandi, D.R. Hicks, R. Gonzalez, L. Cosyns, J. Dubuc, M. Kraml and K.D.G. Edwards: Pharmacokinetics and Disposition of the Lipid-lowering Drug Acifran in Normal Subjects and in Patients with Renal Failure. *Clin. Pharmacol. Therap.* 1990; **47**: 50-56.

M.J. Miller, E.S. Ferdinandi, M. Klan, L.S. Andrews, J. F. Douglas and J.J. Kneiss: Pharmacokinetics and Disposition of Methyl t-Butyl Ether in Fischer-344 Rats. *J. App. Toxicol.* 1997; **17 (S1)**: S3-S12.

E.S. Ferdinandi, D.P. Braun, C. Liu, B.C. Zee and Ely, G: Virulizin - A review of its antineoplastic activity. *Exp. Opin. Invest. Drugs* 1999; **8**: 1721-1735.

K.P. Plotzke, S.D. Crofoot, E.S. Ferdinandi, J.G. Beattie, R.H. Reitz, D.A. McNett and R.G. Meeks: Disposition of radioactivity in Fischer 344 Rats After Single and Multiple Inhalation Exposure to [¹⁴C]Octamethylcyclotetrasiloxane ([¹⁴C]D₄). *Drug Metab. Disp.* 2000; **28**: 192-204.

C. Liu, E.S. Ferdinandi, G. Ely and S. S. Joshi: Virulizin[®]-2γ, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts. *Int. J. Oncol.* 2000; **16**: 1015-1020.

M. Jansen, I. Darby, T. Aribat, P. Dubreuil, E.S. Ferdinandi, J.G. Hardy: Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. *Int. J. Pharmaceut.* 2004; **276**: 75-81.

E.S. Ferdinandi, P. Brazeau, K. High, B. Procter, S. Fennell, P. Dubreuil: Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. *Basic Clin. Pharmacol. Toxicol.* 2007; **100**: 40-58.

POSTER PRESENTATIONS

E.S. Ferdinandi, M.L. Givner, E. Greselin and M.N. Cayen: Metabolic Disposition of Butaclamol Hydrochloride in Rats and Dogs. Presented at the 59th Annual FASEB Meeting, 1975. Fed. Proc. 1975; **34**: 734.

2. E.S. Ferdinandi and M.N. Cayen: Metabolism of Furobufen II. Disposition of [γ - ^{14}C]- γ -oxo-Dibenzofuranbutanoic Acid in Rats and Dogs. Presented at the 61st Annual FASEB Meeting, 1977; Fed. Proc. 1977; **36**: 1032.

E.S. Ferdinandi, M.N. Cayen and C. Pace-Asciak: The Localization and Activity of Pyranoindeole Carboxylic Acids in the Adjuvant Polyarthritic Rat. Presented at the 1979 ASPET Meeting. The Pharmacol. 1979; **21**: 160.

R. Gonzalez, N.M. Cayen, E.S. Ferdinandi, M. Kraml and D. Dvornik: Disposition Studies with AY-25,712, a Novel Antihyperlipidemic Agent. Distribution and Protein Binding in Animals and Serum Levels in Man. Presented at the 1982 ASPET Meeting. The Pharmacol. 1982; **24**: 225.

M.N. Cayen, R. Gonzalez, D. Hicks, E. Greselin, E.S. Ferdinandi and D. Dvornik: Serum Levels, Biotransformation and Excretion of the Antihyperlipidemic Agent 2-Methyl-2-Phenyl-3(2H)-Furanone-5-Carboxylic Acid (AY-25,712) in Rats and Dogs. Presented at the 1982 ASPET Meeting. The Pharmacol. 1982; **24**: 225.

M. Stern, M.N. Cayen, E.S. Ferdinandi, E. Greselin, J. Zilber and D. Dvornik: Serum Concentrations, Tissue Distribution and Excretion of [^{14}C]Cetamolol Hydrochloride in Rats and Dogs. Presented at the 1983 ASPET Meeting. The Pharmacol. 1983; **25**: 111.

E.S. Ferdinandi, M.N. Cayen, M. Kraml and D. Dvornik: Disposition of Etodolac in Man. Presented at the II World Conference on Clinical Pharmacology and Therapeutics. 1983.

M.N. Cayen, D.R. Hicks, E.S. Ferdinandi, M. Kraml, E. Greselin and D. Dvornik: Metabolic Disposition and Pharmacokinetics of the Aldose Reductase Inhibitor Tolrestat in Rats, Dogs and Monkeys. Presented at the 1984 FASEB Meeting. Fed. Proc. 1984; **43**: 750.

J.A. Scatina, D.R. Hicks, E.S. Ferdinandi and M.N. Cayen: Metabolic Disposition of Pelrinone Hydrochloride, a New Cardiotonic Drug, in Dogs and Man. Presented at the 1985 (November) ISSX Meeting.

E.S. Ferdinandi, D.R. Hicks and M.N. Cayen: Disposition of [^{14}C] Tolrestat in Laboratory Animals and Man. Presented at the 1986 FASEB Meeting. Fed. Proc. 1986; **45**: 446.

D.W. Lechner, D.R. Hicks, E.S. Ferdinandi, R. Gonzalez, A.R. Banknieder and M.N. Cayen: Pharmacokinetics and Metabolism of the Antihyperlipidemic Drug Acifran in Rats, Dogs, Mice, Pigs and Man. Presented at the 1986 ASPET-SOT Meeting. The Pharmacol. 1986; **28**: 118.

G. Millington, T. Koziol, T. Ruane, W. Taggart and E.S. Ferdinandi: Disposition of ^{14}C -Diprafenone Hydrochloride in Rat and Dog. Presented at the 1989 FASEB Meeting. Fed. Proc. 1989; **48**: 545.

E.S. Ferdinandi, L. Buchanan, M. Lalande, D. Pilon, G. Lulham, J.-M. Houle, N.P. Skoulis and S. Ridlon: Pharmacokinetics of Tert-Butyl Ether (MTBE) and its Major Circulating Metabolite, Tert-Butyl Alcohol (TBA) in Fischer 344 Rats after Intravenous, Oral and Inhalation Routes of MTBE Administration. Presented at the Third North American ISSX Meeting, San Diego, CA., 1990.

E.S. Ferdinandi, W. O'Neil, J. Barr, E. Romano and G. Worsley: Disposition of Radioactivity in Rats after Single Intravenous Injection of ^{14}C -A Trisaccharide (AT) or ^3H -B Trisaccharide (BT) Ethyl Esters at Doses of 40 mg/Kg. Presented at the Sixth Annual AAPS Meeting, 1991. *Pharmaceut. Res.* 1991; **8**: S-264.

E.S. Ferdinandi, W. O'Neil, M. Lalande, D. Pilon, G. Lulham, N.P. Skoulis and S. Ridlon: Disposition of Radioactivity in Fischer 344 Rats after Intravenous, Oral, Dermal and Inhalation Routes of ^{14}C -Methyl T-Butyl Ether (MTBE) Administration. Presented at the 31st Annual SOT Meeting, 1992. *The Toxicologist* 1992; **12**: 161.

E.S. Ferdinandi, P. Brousseau, J.-M. Houle, P. DiStefano and J.M. Cedarbaum: Pharmacokinetics of Human Recombinant Ciliary Neurotrophic Factor (rHCNTF) in Male and Female Sprague-Dawley Rats after Single Intravenous or Subcutaneous Injections of rHCNTF at a Dose of 1 mg/Kg. Presented at the Fourth North American ISSX Meeting. Bal Harbour, FA., 1992.

J. Chiang, M. Kato, M. Adamo-Trigiani, E.S. Ferdinandi, R. Jackler and M.A. Green: Absorption, Biodistribution and Efficacy of Recombinant Human Basic Fibroblast Growth Factor (bFGF) in Chinchillas. Presented at the AAPS Eight Annual Meeting and Exposition, 1993. *Pharmaceut. Res.* 1993; **10**: S-407.

K.P. Plotzke, S.D. Crofoot, E.S. Ferdinandi, R.G. Meeks and R.W. Mast: Absorption, Distribution and Excretion of ^{14}C -Octamethylcyclotetrasiloxane (D_4) Following Nose-Only Vapor Inhalation Exposure in the Rat. Presented at the 34th Annual SOT Meeting, 1995. *The Toxicologist* 1995; **15**: 194.

R.S. Geary, J.M. Leeds, J. Fitchett, E. Ferdinandi and A.A. Levin: Pharmacokinetics, Tissue Distribution and Excretion of an Antisense Phosphorothioate Oligonucleotide, ISIS 3521 (CGP 64128A) in Rats: IV Bolus vs. Continuous IV Infusion. Presented at the 36th Annual SOT Meeting, March 9-14, 1997. *The Toxicologist*, 1997.

S. Ducharme, E.S. Ferdinandi, S.E. Parker, C.J. Wheller: Disposition of ^3H -Labeled Cytofectin, A Component of a Plasmid-DNA/Cation Lipid Complex, in Mice Following Intravenous Administration. Presented at the 36th Annual SOT Meeting, March 9-14, 1997. *The Toxicologist*, 1997.

C. Liu, H. Mao, S.S. Joshi, J. Harris, B. Zee, E.S. Ferdinandi and G. Ely: A novel immunotherapeutic agent for pancreatic cancer: Results of preclinical and clinical trials. Presented at the 90th ACCR Annual Meeting. *AACR Proceedings* 1999; **40**: 575.

Liu, C.N., Mao, H., Wang, X.J., Halperin, J., Ferdinandi, E.S., and Ely, G.: Inhibition of tumor growth in treatment of human colon cancer and non-small cell lung cancer xenografts by novel dibenzazepines, NC381 and NC384. Presented at the 90th ACCR-NCI-EORTC International Conference, Washington, DC, *AACR Proceedings* 1999; **41**: 192.

E. S. Ferdinandi, D. P. Fitsialos, A. H. Young, J. A. Wright: Toxicokinetics of GTI-2040, a 20mer phosphorothioate oligonucleotide targeting ribonucleotide reductase R2, in Sprague-Dawley rats and rhesus monkeys. *AAPS: 2000 Annual Meeting*, Indianapolis, IN.

G.R. Washer, E. Ferdinandi, B. Procter, J. Praslicka, C. Parente, P. Dubreuil and T. Abribat: TH9507: Safety studies of a growth hormone releasing factor (GRF) analogue. Presented at the 42nd Annual Society of Toxicology Meeting 2003. Abstract No. 222

E. Ferdinandi, G. Washer, L. Pinsonneault, K. Robinson and T. Aribat: TH9507: Embryofetal and fertility studies of a growth hormone releasing factor (GRF) analogue. Presented at the 42nd Annual Society of Toxicology Meeting 2003. Abstract No. 636

K. High, E. Ferdinandi, G. Washer, T. Tsikos, D. Chun, A. Hage, N. Desforges, M. Garino, P. Dubreuil and K. Peri: Pharmacokinetics (PK) of THG213.29 (a 9-mer peptide) and two shorter metabolites (N-1 and N-2) in rats and dogs. Presented at the 2003 AAPS Annual Meeting and Exposition. Abstract No. W5247

E. Ferdinandi, G. Washer, K. High, K. Peri, J. Praslicka, J. Laliberté, C. Thompson, H. Wong: THG213.29: Safety of a Novel Peptide for Treatment of Acute Renal Failure. Presented at the 43rd Annual Society of Toxicology Meeting 2004. Abstract No. 1425.

K. High, H. Deng, T. Tsikos, T. Flarakos, E. Ferdinandi: Quantitative Determination of a 44-Amino Acid Human Growth Hormone Releasing Factor Analogue, TH9507, in Rat and Dog Plasma Using LC/MS/MS. Presented at the 2004 AAPS Annual Meeting and Exposition. Abstract No. M1026

K. Bastian, K. High, M. Greaves, P. Thibault, H. Loughrey, J. Anders, G. Petrie, E. Ferdinandi: Development Of A Peptide Map For TH9507, a 44 Amino Acid Peptide, and HPLC/MS Identification of Degradants of the Peptide. Presented at the 2004 AAPS Annual Meeting and Exposition. Abstract No. T2041

S.W. Fennell, H. Loughrey, M. Garino, S. Abdullah, M. Stilliansesis, K. Arjah, B. Vu, E. S. Ferdinandi: Repeat Dose Toxicity Studies in Rats and Dogs with TH0318, a DPP IV-Resistant Analog of Natural GLP-1. Presented at the 44th Annual Society of Toxicology Meeting 2005. Abstract No. 1780.

K.A. High, A. Gritsas, T. Tsikos, T. Flarakos, E.S. Ferdinandi: Assessment of ex vivo DPP-IV Proteolytic Cleavage of TH9507 in Rat, Dog and Human Plasma by LC/MS. Presented at the X Annual Meeting of the American Society of Mass Spectrometry 2005. San Antonio, TX

H. Loughrey, L. Liu, D.M. Brochu, F. Polyak, E. Ferdinandi: Development of a sensitive Sandwich ELISA for detecting full length biologically active TH0318, a new GLP-1 analogue. Presented at the 2005 AAPS Annual Meeting and Exposition. Abstract No. W5009

A. Martel, M. Marcoux, J. Couture, M. Garino, K. High, F. Vallée, E. Ferdinandi: Enzyme linked immunosorbent assay (ELISA) method for the determination of TH0318, a new GLP-1 analogue in development for diabetes. Presented at the 2005 AAPS Annual Meeting and Exposition. Abstract No. W5008

H. Loughrey, R. Riffon, A. Michaux, E. Ferdinandi: Epitope profiling of anti-TH9507 antibodies in dogs illustrates present limitations of immunogenicity screening assays. Presented at the 2006 AAPS National Biotechnology Conference. Abstract No. T2029

ORAL PRESENTATIONS

E. Ferdinandi: Analytical Challenges in the Development of Novel Peptide Therapeutics. Presented as part of a symposium on drug development sponsored by MDS Pharma Services, Montréal, 2004.

E. Ferdinandi: Determination of a novel therapeutic peptide – Immunoassay *versus* LC-MS/MS. Presented as part of a symposium on the Determination of Therapeutic Proteins, Peptides and Oligonucleotides in Biological Matrices at the 2005 Annual AAPS Meeting.

PATENTS

J.F. Bagli, E.S. Ferdinandi: Thiophene Ethanolamines. **U.S. Patent 4,093,628**. June 26, 1978.

K. Sestanj, E.S. Ferdinandi: N-[[5-(trifluoromethyl)-6-methoxyl-naphthalenyl] thioxomethyl and carbonyl]-methylglycinamides. **U.S. Patent 4,672,059**. June 9, 1987.

E.S. Ferdinandi, M. Malamas, K. Sestanj, S. Sehgal: N-[[6-methoxy-5-(trifluoromethyl)-1-naphthalenyl]-thioxomethyl]-N-methylglycine S-oxide and the amide thereof. **U.S. Patent 4,994,381**. February 19, 1991.